Abstract Invasive lobular carcinoma (ILC) is more frequently lymph node positive than is invasive ductal carcinoma (IDC), and ILC cell infiltration shows distinctive histological characteristics, suggesting the action of ILC-specific invasion molecules. To identify such a molecule, we used a proteomic approach in the pseudopodia of MDA-MB-231 breast cancer cells. A pseudopodial constituent was identified using excimer laser ablation, two-dimensional difference gel electrophoresis, mass spectroscopy, and immunocytofluorescence. MDA-MB-231 cells were modified to express various levels of this constituent by transient transfection and were examined for pseudopodia formation and migratory abilities using wound healing and two-chamber assays. Immunohistochemical positivity of human breast cancer cells (56 ILCs and 21 IDCs) was compared with clinicopathological variables. An actin-binding adaptor protein, a-parvin, was found to localize to pseudopodia and to form focal adhesions in cells not induced to extend pseudopodia. Pseudopodial length and density and migratory abilities correlated with a-parvin expression. Twenty-one (37.5 %) ILCs stained positive for a-parvin, whereas the results were negative for all 21 IDCs (P \ 0.001). a-Parvin positivity in ILC was significantly associated with lymphatic invasion (P = 0.038) and lymph node metastasis (P = 0.003) in univariate analyses and to lymph node metastasis (P = 0.020) in multivariate analyses. a-Parvin, a pseudopodial constituent, was found to promote migration of breast cancer cells and to be expressed exclusively by ILC, suggesting that a-parvin is an ILC-specific invasion molecule that may have clinical utility as a biomarker for aggressive subsets of ILC.
Introduction
Invasive lobular breast carcinoma (ILC) is characterized by a distinctive histological appearance, consisting of small round or spindle-shaped non-cohesive cells that grow in a single-file pattern to infiltrate the adjacent stroma [1] . Typically, these cytologic and histopathologic features readily distinguish ILC from invasive ductal carcinoma (IDC) [1] . ILC and IDC also differ clinically. In a stagematched comparison, the 5-year disease-specific survival was significantly better for patients with ILC than for IDC patients, whereas ILC is more likely to be lymph node positive [2] . In addition, the metastatic pattern of ILC differs from that of IDC. ILC has higher frequency of metastasis to bone, gastro-intestinal tract, uterus, and ovary, while pulmonary metastasis is more frequent in IDC [1] . These differences suggest ILC has specific machinery for invasion and metastasis, distinct from that of IDC. Recent comprehensive gene expression profiling successfully clarified cell lineage difference between ILC and IDC, but has not led to the identification of key mechanisms for this suggestion [3] [4] [5] .
Pseudopodia are cytoplasmic protrusions at the leading edge of migrating cells [6] . The ability of tumor cells to form pseudopodia is important for tumor cell invasion and metastasis [7] . Recently, we established a method for selective collection of pseudopodial proteins by applying a fine-tuned cell etching technique assisted by excimer laser ablation [8] . With this method, pseudopodial protein extracts were prepared from MDA-MB-231 cells, a highly invasive and metastatic human breast cancer cell line, and analyzed by two-dimensional difference gel electrophoresis (2D-DIGE). Mass spectroscopy revealed the pseudopodial extracts were rich in pseudopodium-localizing molecules [8] . In our continuing effort to screen the pseudopodial extract by 2D-DIGE, we found a new candidate protein and identified it as a-parvin by mass spectrometry.
a-Parvin, also called actopaxin, is an adaptor protein consisting of an N-terminal polypeptide followed by 2 calponin homology domains arranged in tandem [9, 10] . This domain structure enables a-parvin to recruit filamentous actin (F-actin) to its localization site and associate with stress fibers [10, 11] . In addition, via the C-terminal calponin homology domain, a-parvin binds a variety of partner molecules including integrin-linked kinase and paxillin [10, 12] . In spreading cells on extracellular matrices, a-parvin associates with the cytoplasmic domains of integrins and thereby localizes to integrin-mediated cellmatrix adhesion sites or focal adhesions [10, 13, 14] . Additional localization sites are peripheral lamellar ruffles and perinuclear regions [10, 11] . Based on these molecular features, a-parvin is assumed to play prominent roles in integrin-mediated adhesion and actin-dependent processes such as cell shape regulation and cell migration [15, 16] . Although the involvement of a-parvin in cancer cell invasion has been demonstrated in vitro [17] , a-parvin expression and its clinical significance in human tumors including breast cancer have not been elucidated.
In this study, we first identified a-parvin as a pseudopodium-localizing molecule by mass spectroscopy and immunocytofluorescence analyses. Next, we examined whether a-parvin contributes to pseudopodium formation and cell migration. MDA-MB-231 cells were modified to express increased or decreased levels of a-parvin by transient transfection with the full-length cDNA and small interfering RNA (siRNA) targeting a-parvin and were analyzed for their abilities to form pseudopodia and migrate directionally using wound healing and doublechamber transmigration assays. We also examined a-parvin expression in human breast cancers selected from our 1782 of cases and evaluated its clinical significance. We conducted immunohistochemical staining for a-parvin on surgical specimens of ILC and IDC, and analyzed the association between a-parvin-positivity and various clinicopathological parameters.
Materials and methods

Cells, antibodies, and reagents
The MDA-MB-231 breast cancer cell line was purchased from American Type Culture Collection (Rockville, MD) and cultured as described previously [8] . The following primary antibodies were used: anti-a-parvin antibody (for western blotting, ab139270, Abcam, Cambridge, England; for immunohistochemistry, HPA005964, Sigma-Aldrich, St. Louis, Missouri, USA); antibody against a-parvin phosphorylated at Serine 8 (mainly for immunofluorescence, ab79409, Abcam); anti-paxillin antibody (610620, BD Biosciences, Franklin Lakes, NJ); and anti-b-actin antibody (Sigma-Aldrich). Peroxidase-and fluorophoreconjugated secondary antibodies were obtained from Amersham (Buckinghamshire, England) and Jackson ImmunoResearch (West Grove, PA, USA), respectively. Phalloidin-tetramethylrhodamine B isothiocyanate was purchased from Sigma-Aldrich.
Pseudopodial proteomics
Proteomic analyses of pseudopodia from MDA-MB-231 cells were conducted as described [8] . In brief, 1 9 10 5 MDA-MB-231 cells were cultured in a 12-well dish, with the well bottoms coated with a fibronectin-coated polyethylene terephthalate membrane with multiple pores (3-lm diameter), and were induced to extend pseudopodia into the pores with NIH3T3-conditioned medium for 2 days. Pseudopodia were selectively collected by excimer laser ablation-assisted cell etching using a keratectomy system (EC-5000 CXIII, Nidek, Gamagori, Japan). Pseudopodial protein extracts were analyzed by 2D-DIGE with whole cell extracts as controls. Protein spots of interest were identified by liquid chromatography-tandem mass spectroscopy (LC-MS/MS; Finnigan LTQ linear ion trap mass spectroscopy, Thermo Electron, San Jose, CA) and the Mascot database search algorithm (Matrix Science, London, UK).
Exogenous expression and knockdown of a-parvin
The full-length cDNA for human a-parvin was obtained by reverse transcriptase-polymerase chain reaction using total RNA from MDA-MB-231 cells and primers: sense, 5 0 -CTGCCTCAAATGCTTGGAAT-3 0 (start codon, underlined) and antisense, 5 0 -CAGTACGCCAACAGCAAGAA-3
0 . Approximately 1.3-kbp-long PCR-amplified cDNA was inserted into pTA2 TA-cloning vector (Toyobo, Osaka, Japan). After amplification, the insert was excised by EcoRI digestion and ligated into pCX4bsr [18] 0 -UCUUUCACAAUGAUUCUUUCT-3 0 ) were purchased with control siRNA (In Vivo Negative Control #1 siRNA) from Ambion (Life Technologies). MDA-MB-231 cells were transfected with these siRNAs using X-tremeGENE siRNA transfection reagents (Roche, Basel, Switzerland) according to the manufacturer's instructions.
Western blotting
Western blotting was performed as described previously [19] and immunoreactive band intensities were quantified by the AlphaEaseFCTM software (Alpha Innotech Corp., San Leandro, CA). Transfected and untransfected MDA-MB-231 cells were blotted after 2 days of transfection. a-Parvin expression in transfectants was calculated by dividing a-parvin intensity by b-actin intensity and normalized to 1 for untransfected MDA-MB-231 cells.
Length and density of pseudopodia After 2 days of transfection, 1 9 10 4 transfected or untransfected MDA-MB-231 cells were cultured on the porous membrane and induced to extend pseudopodia for 2 days under the conditions described for pseudopodial proteomics. The cells on the membrane were fixed with 4 % paraformaldehyde, stained with phalloidin for 1 h at room temperature, and observed by confocal scanning laser microscopy (FV1000D IX81, Olympus, Tokyo, Japan). Multiple X-Y plane images were captured using a 0.15-lm motor step along the Z axis. Z plane views of pseudopodia were reconstituted by stacking the X-Y plane images and the Z-axial lengths of 200 pseudopodia were measured for each cell type. The area encircled by the peripheral margin of individual cells in X-Y planes was measured using ImageJ software and the number of pseudopodia in this area was counted. Thirty cells were analyzed per membrane, and the sum of the number of pseudopodia divided by the sum of the cell areas was expressed as pseudopodial density (number/lm 2 ). The mean density and standard error (SE) were calculated from triplicate sets. Experiments were repeated 3 times using MDA-MB-231 cells transfected individually in each experiment, with essentially similar results.
In vitro cell migration assays Two-chamber transmigration and wound healing assays were conducted as described [20, 21] . For transmigration assays, 2.5 9 10
5 MDA-MB-231 cells were seeded in a 12-well culture insert with a fibronectin-coated polyethylene terephthalate membrane with multiple pores (8 lm in diameter) placed at its bottom and were induced to transmigrate through the pores with NIH3T3-conditioned medium. After 3 and 6 h, cells were stained with phalloidin and the number of cells on the underside of the porous membrane was counted per 10 high-power (4009) fields using a fluorescence microscope. For wound healing assays, MDA-MB-231 cells were grown to confluence in 35-mm culture dishes with a coverslip-like bottom (l-Dish; Ibidi, Munich, Germany), and a liner wound was created in the cell monolayer by scratching the dish with a 200-ll pipet tip. At 0, 6, and 12 h after scratching, the wounded cell culture was photographed with a CCD camera-equipped microscope and the wounded, acellular area was measured using ImageJ software. The acellular areas at 6 and 12 h were expressed as relative values (%) to the areas at 0 h. In these assays, the mean and SE were calculated from triplicate sets. Both assays were repeated three times using MDA-MB-231 cells transfected individually prior to each assay, with essentially similar results.
Human breast cancer specimens
Human breast cancer specimens were obtained from patients diagnosed with breast cancer who underwent tumor removal surgery at Kinki University Hospital (Osaka-Sayama, Japan) between August 2003 and December 2013. The total number of removed breast cancers was 1568. Tumors from patients who received preoperative chemotherapy were excluded. Fifty-six ILCs available were all used in this study. Twenty-one IDCs were selected so that they included seven tumors from each of the three major histological subtypes (papilla-tubular, solid-tubular, and scirrhous), and the proportion of lymph node metastasis-positive tumors was equivalent to that in ILCs. Tumor specimens were fixed with 10 % buffered formalin, embedded in paraffin, cut into sections (4-lm thick), and stained with hematoxylin and eosin (H&E). Pathological diagnosis was made by two independent pathologists according to WHO [1] and TNM [22] classifications. Sections were also examined by immunohistochemistry for epidermal growth factor and hormone receptors, and immunohistochemical positivity was evaluated according to published guidelines [23, 24] . The ethics committee of Kinki University Faculty of Medicine approved the experimental protocol (No. 22-40).
Immunocytofluorescence and Immunohistochemistry MDA-MB-231 cells were grown to 70 % confluence in fibronectin-coated glass-bottomed dishes (Iwaki, Tokyo, Japan) or in fibronectin-coated porous membrane-bottomed culture inserts as described above. The immunocytofluorescence procedures were similar to those described previously [19] . In brief, cells were fixed with 4 % paraformaldehyde and permeabilized with 0.25 % Triton-X. Nonspecific Ig binding was blocked with 2 % bovine serum albumin. Cells were incubated with a mixture of antibodies against a-parvin (ab79409; 1:100 dilution) and paxillin (1:100 dilution) and visualized with Alexa Flour 488-and Cy3-conjugated secondary antibodies, respectively. In some experiments, cells were reacted serially with the a-parvin antibody and Alexa Flour 488-conjugated secondary antibody, and then stained with phalloidin. Fluorescence images were captured using a C2? confocal scanning system equipped with 488-nm argon and 543-nm helium-neon lasers (Nikon, Tokyo, Japan). Immunohistochemistry for breast cancer specimens was conducted as described [18] using the a-parvin antibody (1:50; HPA005964). Tumors were deemed positive for a-parvin when the cell membrane or cytoplasm of over half of the tumor cells was intensely stained.
Statistical analysis
Measured values for pseudopodia and migratory abilities were compared by Mann-Whitney U test. Correlations of a-parvin expression with migratory abilities were analyzed by Spearman's rank test. Associations between clinicopathological variables and a-parvin immunohistochemical positivity were assessed by the Mann-Whitney U test for continuous variables and the v 2 test for categorical variables. In v 2 tests, Yates' continuity correction was adopted if the number of cases was\5 for one factor or[4 and\11 for 2 factors. All variables including a-parvin positivity were univariately analyzed on lymphatic invasion and lymph node metastasis; then, all variables that had P values less than 0.05 were included in multivariate logistic regression analysis. All tests were two-tailed, and a P value \ 0.05 was considered significant.
Results and discussion
Identification of a-parvin as a pseudopodial constituent
As reported previously [8] , MDA-MB-231 cells were cultured on fibronectin-coated porous membranes and induced to extend pseudopodia. Pseudopodial protein extracts were obtained by excimer laser ablation-assisted cell etching and analyzed by 2D-DIGE in comparison with the whole cell extract. We found a protein spot that was more intense in the pseudopodial extract than in the whole cell extract (supplemental Fig. S1 ). This spot was analyzed by LC-MS/ MS and identified as a-parvin (supplemental Fig. S1 ).
MDA-MB-231 cells extending pseudopodia were doublestained by a-parvin immunofluorescence and phalloidin, which binds F-actin. We used an antibody against a phosphorylated form of a-parvin (ab79409), because this form promotes cancer cell invasion [17] . Pseudopodia, which are rich in F-actin, were easily visualized by phalloidin fluorescence (Fig. 1b) . Consistent with our proteomic result, immunostaining for a-parvin was abundant in pseudopodia (Fig. 1b) . Nuclear staining was also evident, consistent with previous reports in other cell types [10, 11] . Next, MDA-MB-231 cells were double stained for a-parvin and paxillin, a focal adhesion-associated adaptor protein [25] . When cells were cultured in fibronectin-coated glassbottomed dishes, a-parvin, together with paxillin, localized specifically to focal adhesions and diffusely to the cytoplasm and nucleus (Fig. 1c, upper) . Similar immunofluorescence analysis was conducted in MDA-MB-231 cells with extended pseudopodia. Immunostaining for a-parvin and paxillin were easily detected in the pseudopodia (Fig. 1c, lower) . Although a considerable amount of paxillin was detected at focal adhesions, a-parvin was nearly absent from focal adhesions (Fig. 1c, middle) . a-Parvin appeared to preferentially localize to pseudopodia rather than focal adhesions in MDA-MB-231 cells with extended pseudopodia.
a-Parvin promotes pseudopodium formation and migration of MDA-MB-231 cells
To probe the role of a-parvin in pseudopodia, we modified MDA-MB-231 cells to express variable levels of a-parvin by transient transfection. In transfectants with the full-length aparvin cDNA, a-parvin levels were 2.2-fold that in untransfected cells and reduced by 60-70 % in cells transfected with siRNAs targeting a-parvin (siRNAs #1 and #2) (supplemental Fig. S2 ). Expression of a phosphorylated form of a-parvin similarly increased or decreased in these transfectants (supplemental Fig. S2 ). Three types of transfection were conducted in parallel and after 2 days, transfected and untransfected cells were plated onto porous membranes and induced to extend pseudopodia. After 2 days, pseudopodia were visualized using phalloidin staining, and the length and density (number per cell area) of pseudopodia were measured for each cell type (Fig. 2a) . Triplicate sets of experiments revealed that a-parvin overexpression significantly increased pseudopodia length, whereas a-parvin knockdown by siRNAs significantly reduced the length and density of pseudopodia (Fig. 2b) . Transfected and untransfected cells were examined for their migratory ability by two-chamber transmigration and wound healing assays. In transmigration assays, transfected and untransfected cells were plated on 8-lm porous membranes and induced to transmigrate across the membrane through the pores. At 3 and 6 h after plating, the number of cells on the underside of the porous membrane was counted (Fig. 3a) . Knockdown of a-parvin significantly reduced the number of transmigrated cells at either time point (Fig. 3b) . The reverse was observed with a-parvin overexpression; the increase in transmigrated cell number was significant at 6 h (Fig. 3b ). Experiments were repeated three times using MDA-MB-231 cells individually transfected prior to each set of assays. The number of transmigrated cells at 6 h after scratching inversely correlated with a-parvin expression (Fig. 3c) .
In wound-healing assays, confluent cell cultures were wounded by scratching, and wound closure was monitored at 6 and 12 h by measuring the acellular wound areas (Fig. 4a) . At each time point, the wound area was smaller in a-parvinoverexpressing cells and larger in a-parvin-knocked-down cells than in untransfected cells; these differences reached statistical significance at 12 h (Fig. 4b) . Three independent experiments using individually transfected cells revealed that the wound area at 12 h correlated with a-parvin level (Fig. 4c) . The cultures of untransfected cells at 6 h after wounding were double-stained with a-parvin immunofluorescence (green) and phalloidin fluorescence (red) (Fig. 4d) . Cells on the front line of the wound often formed membrane ruffles at the leading edge, called lamellipodia, which are a flat veil form of pseudopodia [6] . These structures were recognizable by dense phalloidin labeling (Fig. 4d) . In these cells, a-parvin was detected on the peripheral margin of the lamellipodia and was localized to focal adhesions, not to the cell membrane, in cells in the second line of the wound (Fig. 4d) . These results suggest a-parvin plays a critical role in directional cell migration by localizing to and elongating pseudopodia and lamellipodia. a-Parvin is independently associated with lymph node metastasis of ILC a-Parvin expression was assessed in formalin-fixed, paraffin-embedded ILCs (n = 56) and IDCs (n = 21). Patient Fig. 2 Critical roles for a-parvin in pseudopodium formation. MDA-MB-231 cells were transfected with a-parvin-targeting siRNAs (#1 and #2) or a-parvin cDNA. Transfected and untransfected cells were induced on porous membranes to extend pseudopodia for 2 days and pseudopodia were visualized by phalloidin staining. X-Y plane and Z sectional views of pseudopodia were generated by confocal scanning laser microscopy (a) and the length and density (number per cell area) of pseudopodia were calculated. The mean length and density were plotted with bars indicating SE in (b). *P \ 0.01 by Mann-Whitney U test versus untransfected cells. Arrowheads in a indicate nonspecific labeling of empty pores (without pseudopodia) by phalloidin. Bar in a, 2 lm characteristics are summarized in Table 1 and Supplemental Table S1 . Twenty-one (37.5 %) ILCs were immunohistochemically positive for a-parvin. Positive staining was mainly diffuse in the cytoplasm and occasionally on the cell membrane (Fig. 5) . In contrast, all IDCs were negative for a-parvin (P \ 0.001) (supplemental Fig. S3 ). In the context of various clinicopathological variables, aparvin-positive ILCs were more likely to invade lymphatic vessels (P = 0.038) and metastasize regional lymph nodes (P = 0.003) than were negative ILCs (Table 1) . In univariate analyses of 11 assessed variables, only 2, a-parvin positivity and lymphatic invasion were correlated with lymph node metastasis (supplemental Table S2 ). These correlations were verified to be independent of each other by multivariate analyses (supplemental Table S2 ). Univariate analysis also identified a-parvin positivity and lymph node metastasis as variables associated with lymphatic invasion, although a-parvin positivity did not remain significant in multivariate analysis (supplemental Table  S3 ). These results indicate a-parvin can be a biomarker for aggressive subsets of ILC, although mechanisms for its restricted expression to ILC remain to be addressed. We are planning a follow-up study of patients with a-parvinpositive and -negative tumors to evaluate the utility of aparvin as a prognostic biomarker of ILC. ILC is more frequently lymph node positive than is IDC, and has a distinctive histological appearance, which consists of noncohesive cells that are individually dispersed through a fibrous connective tissue or arranged in single-file linear cords that invade the stroma. These clinical and a According to TNM classification [22] b According to WHO classification [1] c Human epidermal growth factor receptor 2 d Negative for estrogen receptor, progesterone receptor, and HER2
histological features are assumed to be attributable to loss of E-cadherin, an intercellular adhesion molecule involved in adherens junction formation [1, 26] . Restricted expression of a-parvin to ILC and its correlation with the aggressive phenotype suggest upregulation of a-parvin is another key event for manifestation of these features in ILC. Recently, Turner and co-workers [17] reported localization of a-parvin to invadopodia, specialized adhesion microstructures that degrade underlying extracellular matrices. Pseudopodia and invadopodia have distinct roles in tumor cell invasion in vivo. The primary role of invadopodia is to degrade extracellular matrices at the leading edge of the invading cell, subsequently resulting in widening of the pericellular space for pseudopodiummediated migration [7] . This high degree of crosstalk between pseudopodia and invadopodia is required for efficient invasion coupled with migration [7] . Because a-parvin appears to localize to both pseudopodia and invadopodia, it is expected to play a unique, indispensable role in lymphatic invasion and metastasis of ILC.
In conclusion, we identified a-parvin as a pseudopodial constituent that promotes migration of breast cancer cells and is expressed in ILC, not IDC. This study proposes a-parvin to be an ILC-specific molecule involved in tumor invasion, and suggests its clinical utility as an ILC-specific biomarker for identifying aggressive subsets. This study also demonstrates that proteomic approach to pseudopodia is a simple and straightforward way to search cancer biomarkers. Further promotion of pseudopodial proteomics and further characterization of a-parvin as a pseudopodial adaptor protein will provide a deeper understanding of molecular mechanisms specific to ILC invasion and metastasis.
